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Aim: To evaluate the risk of urinary tract infections (UTI) in subjects with newly diagnosed type 2 diabetes
mellitus (T2DM).
Methods: Subjects aged ≥18 years and diagnosed with T2DM between 1/1/10 and 12/31/10 were identiﬁed
using the MarketScan® databases, which are representative of the commercially insured US population and
those with both Medicare and supplemental coverage. The index date was the ﬁrst T2DM diagnosis date in
2010 (date randomly selected for those without T2DM). Subjects without T2DMwerematched (1:1) by index
date, age, gender, urban/rural location, and region. All subjects had continuous enrollment for 12 months
before (baseline) and after (follow-up) the index date. UTI diagnosis was deﬁned using ICD-9-CM codes.
Measurements of glycemic control and body weight were not available. An adjusted logistic regression model
assessed the likelihood of UTI.
Results: A total of 89,790matched pairs were selected. During follow-up, a UTI diagnosis wasmore common in
subjects with T2DM than without T2DM (9.4% vs. 5.7%; p b 0.0001). Recurrence of UTI was also more likely
with T2DM (1.6% vs. 0.6%; p b 0.0001). In a logistic regression, subjects with T2DM had a greater likelihood of
UTI during follow up (adjusted odds ratio [OR] = 1.54 [95% CI: 1.47–1.60]). This relationship remained after
stratifying by gender.
Conclusion: Subjects with T2DM were more likely to experience a UTI and recurrent UTIs than subjects
without T2DM during follow-up.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Diabetes mellitus is a progressive disease that is characterized by a
state of chronic hyperglycemia. Currently, diabetes affects an estimated
366millionpeopleworldwide, but this number is only expected to rise. By
2030, it is estimated that 552 million people will have diabetes
(International Diabetes Federation, 2011). Type 2 diabetes mellitus
(T2DM) is the most common form of diabetes, accounting for approxi-
mately 85% to 95% of all cases worldwide (International Diabetes
Federation, 2011). A diagnosis of T2DM brings with it a vast array ofn at the American Diabetes
linois; June 21–25, 2013.
research support fromMerck &
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tion, NJ 08889. Tel.: +1 908
Inc. This is an open access article udiabetes-related complications that result in signiﬁcant morbidity and
mortality. Recently, the role of urinary tract infections (UTI) has been
evaluated in several studies as a potential complication of T2DM. Findings
suggest that these infections are more commonly experienced by those
with T2DM compared to those without T2DM (Boyko, Fihn, Scholes,
Abraham, & Monsey, 2005; Geerlings et al., 2000; Geerlings et al., 2001;
Goswamiet al., 2001;Hirji, Guo,Andersson,Hammar,&Gomez-Caminero,
2012; Jackson et al., 2004; Muller et al., 2005; Sotiropoulos et al., 2005).
Although the exact mechanism is unknown, several possibilities
have been proposed to explain the association between diabetes and
UTI. For example, damage to the genitourinary system as a result of
diabetic neuropathy could lead to a dysfunctional bladder, thereby
creating the opportunity for UTI development (American Diabetes
Association, 2013; Brown et al., 2005; Hosking, Bennett, & Hampton,
1978). The presence of higher glucose concentrations in the urine
might present another pathway for UTI development by amplifying
bacterial reproduction, which creates a favorable environment for
infections (Chen, Jackson, & Boyko, 2009; Fünfstück, Nicolle, Hanefeld
and Naber, 2012; Geerlings et al., 2000). Patient-related factors such
as age, metabolic control and duration of diabetes have also beennder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Study Design. Note: For subjects with T2DM, the index date was the ﬁrst date of
T2DM diagnosis in 2010. For those without T2DM, the index date was randomly
selected in 2010.
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diabetes (Brown et al., 2005; Fünfstück et al., 2012; Turan et al., 2008).
Moreover, impaired immune response may play a role in the patient's
decreased ability to defend against bacterial proliferation (Geerlings &
Hoepelman, 1999; Valerius et al., 1982).
Although previous studies have cited an increased risk of UTIs in
subjects with diabetes, the majority of published data are from small,
single-center studies, and the availability of US population-based data is
lacking. The objective of this study is to use a large US-based healthcare
claimsdatabase to examine the prevalence, incidence, and risk of urinary
tract infections in subjects with and without newly diagnosed T2DM.
2. Materials and methods
2.1. Data source
The matched study cohort was derived from the Truven Health
MarketScan® Commercial Claims and Encounters and Medicare
Supplemental and Coordination of Beneﬁts Databases. These data
include paid, patient-level medical and pharmacy claims histories of
110 million covered participants belonging to 12 national and
regional health plans in the US. The Commercial and Medicare
Supplemental Databases are considered representative of the national
commercially insured population and those who have both Medicare
and supplemental employer-sponsored coverage. The extracted data
included all enrollment records and inpatient, outpatient, ancillary,
and drug claims. This analysis included data from Commercial Claims
and Encounters and Medicare Supplemental and Coordination of
Beneﬁts databases from January 1, 2009 to December 31, 2011.
2.2. Patient selection
In this retrospective, matched cohort study, subjects 18 years of
age or older with newly diagnosed T2DM between January 1, 2010
and December 31, 2010 were identiﬁed using the International
Classiﬁcation of Disease, 9th Revision, Clinical Modiﬁcation (ICD-9
CM) diagnostic codes (250). The ﬁrst date of T2DMdiagnosis recorded
in 2010 in the database was deﬁned as the index date. Subjects were
excluded if they had a diagnosis of T2DM or antihyperglycemic
medication use in the year prior to the index date. In addition, subjects
with type 1 diabetes mellitus (ICD-9-CM codes 250.x1 and 250.x3),
gestational diabetes mellitus, or other forms of secondary diabetes
were excluded. Subjects were required to have continuous enrollment
in the database during the 12 months preceding (baseline period) and
12 months following (follow-up period) the index date. Subjects
without T2DM were deﬁned as those without a T2DM diagnosis or
any antihyperglycemic medication use between January 1, 2009 and
December 31, 2011. They were randomly assigned an index date in
year 2010, and the same aforementioned inclusion/exclusion criteria
were applied. From this group, a cohort of subjects without T2DMwas
selected by matching the subjects with T2DM in a 1:1 ratio. Matching
criteria included index date (same year and month), age at the index
date within 5 years, gender, urban/rural location (deﬁned using
metropolitan statistical area [MSA]), and geographic region (north-
east, north central, south, or west). Patient characteristics, including
demographics and comorbid disease conditions, were assessed for all
subjects during the 12-month baseline period. The ICD-9-CM codes
were used to determine the presence of baseline comorbidities.
2.3. Outcome assessment
Subjects were followed for one year after their index date to
determine whether a UTI event had occurred (Fig. 1). A UTI event was
deﬁned as experiencing one or more of the following diagnoses
during the follow-up period: UTI (ICD-9-CM Code 599.0), cystitis
(ICD-9-CM Code 595), or pyelonephritis (ICD-9-CM Code 590.1 or590.0). ICD-9-CM codes for UTI were selected based on a review of
deﬁnitions used in the literature and clinical consultation and
consensus. When examining the rate of recurrent infections, UTI
claims at least 3 months apart were considered as separate
UTI events.
2.4. Statistical analysis
Baseline characteristics of subjects with and without T2DM were
summarized and compared using the Student's t-test for continuous
variables and the chi-square or Fisher's exact test for categorical
variables. The prevalence cohort consisted of all subjects regardless of
UTI history, and the incidence cohort contained only those subjects
without a history of UTI during the baseline period. An adjusted
multivariate conditional logistic regression analysis was performed to
evaluate the association between UTIs and T2DM for our sample of
matched pairs. The regression was performed adjusting for health
insurance plan, baseline comorbidities (microvascular complications,
cardiovascular conditions, chronic renal disease, liver disease, and
hypoglycemia), baseline UTI, and number of physician visits in the
baseline period. Due to possible differential effects by age and gender
groups, signiﬁcance tests for the interaction terms between T2DM and
age, as well as T2DM and gender, were performed. Additionally,
subgroup analyses were conducted by age and gender groups.
3. Results
A total of 179,580 subjects (89,790 matched pairs) were selected
for inclusion in this analysis. At baseline, subjects had a mean age of
56 years, and 50.8% were male. Subjects with newly diagnosed T2DM
had more pre-existing comorbid conditions compared to subjects
without T2DM, and also had a higher rate of baseline UTI (8.4% vs.
5.4%; p b 0.0001). A detailed listing of all baseline characteristics for
the study cohort is presented in Table 1.
3.1. Prevalence cohort (all subjects)
When examining all subjects, 7.6% were diagnosed with a UTI
during the one year follow up period. A UTI diagnosis was more
common in those with newly diagnosed T2DM than in those without
T2DM (9.4% vs. 5.7%; p b 0.0001). When exploring the individual
components of our composite UTI deﬁnition, subjects with T2DM
were more likely to have a diagnosis of UTI, cystitis, or pyelonephritis
compared to subjects without T2DM (8.6% vs. 5.1%, 1.34% vs. 0.9%, and
0.14% vs. 0.07% respectively; p b 0.0001 for all comparisons). More
women experienced UTI than men, but in both men and women, the
occurrence of UTI was higher in those with T2DM than those without
T2DM (women: 14.0% vs. 9.1%;men: 5.0% vs. 2.4%; p b 0.0001 for both
groups). At each age group, a larger proportion of subjects with T2DM
than those without T2DM had a UTI during follow-up, and this
relationship remained even after stratifying by gender (Table 2,
Table 1
Baseline characteristics of T2DM subjects vs. non-T2DM subjects (N = 179,580).
T2DM Without T2DM p Value
n Mean (SD) or % n Mean (SD) or %
Age at the index date, yr⁎ 89,790 56.0 (13.4) 89,790 56.0 (13.4) 0.95
Age groups (yr)⁎ 1.00
18–24 1175 1.3% 1174 1.3%
25–34 3,335 3.7% 3,338 3.7%
35–44 11,556 12.9% 11,555 12.9%
45–54 24,890 27.7% 24,894 27.7%
55–64 30,719 34.2% 30,728 34.2%
65–74 8,599 9.6% 8,594 9.6%
75 and above 9,516 10.6% 9,507 10.6%
Gender⁎ 1.00
Female 44,222 49.3% 44,222 49.3%
Male 45,568 50.8% 45,568 50.8%
Rural (vs. urban)⁎ 12,015 13.4% 12,015 13.4% 1.00
Region⁎ 1.00
Northeast 22,156 24.7% 22,156 24.7%
North central 19,384 21.6% 19,384 21.6%
South 32,614 36.3% 32,614 36.3%
West 15,521 17.3% 15,521 17.3%
Health plan b0.0001
Comprehensive 13,637 15.7% 13,537 15.5%
EPO 2,920 3.4% 2,051 2.4%
HMO 13,420 15.4% 14,025 16.1%
POS 10,279 11.8% 9,073 10.4%
PPO 42,962 49.4% 43,147 49.4%
POS with capitation 234 0.3% 283 0.3%
CDHP 2,864 3.3% 3,962 4.5%
HDHP 678 0.8% 1,281 1.5%
Microvascular complications 5,141 5.73% 2,732 3.04% b0.0001
Retinopathy/Blindness 169 0.19% 14 0.02% b0.0001
Neuropathy 3,196 3.56% 1,828 2.04% b0.0001
Nephropathy 1,879 2.09% 927 1.03% b0.0001
Cardiovascular conditions 14,070 15.67% 7,772 8.66% b0.0001
Stroke 1,030 1.15% 492 0.55% b0.0001
TIA 1,029 1.15% 630 0.70% b0.0001
Congestive heart failure 2,843 3.17% 1,135 1.26% b0.0001
Myocardial infarction 1,314 1.46% 667 0.74% b0.0001
Ischemic heart disease, including angina 9,548 10.63% 5,390 6.00% b0.0001
PAD 3,572 3.98% 1,721 1.92% b0.0001
Chronic renal disease 2,111 2.35% 1,039 1.16% b0.0001
Liver disease 1,765 1.97% 610 0.68% b0.0001
Diagnosis of hypoglycemia 582 0.65% 117 0.13% b0.0001
Baseline UTI 7,551 8.4% 4,849 5.4% b0.0001
Pre-index physician visits 89,790 12.8 (15) 89,790 9.6 (12.2) b0.0001
EPO: exclusive provider organization, HMO: health maintenance organization, POS: point of service, PPO: preferred provider organization, CDHP: consumer-driven health plan;
HDHP: high deductible health plan.
⁎ Variable was used for matching.
807A.Z. Fu et al. / Journal of Diabetes and Its Complications 28 (2014) 805–810Fig. 2). Recurrence of UTI was also higher in subjects with T2DM than
in those without T2DM (1.6% vs. 0.6%; p b 0.0001) during follow up.
3.2. Incidence cohort
Of those subjects without a history of UTI during the baseline
period, 5.8% experienced a UTI during follow-up. Similar to the results
seen for all subjects in the prevalence cohort, a larger proportion of
subjects with T2DM experienced a UTI compared to those without
T2DM (7.2% vs. 4.4%, p b 0.0001), and this relationship remained for
each gender, age group, and component of our composite UTI
deﬁnition (Table 2).
3.3. Multivariate logistic regression
After adjusting for age (continuous in years), health plan, baseline
comorbidities, baseline UTI, and number of physician visits in the
pre-index year, subjects with T2DM had a higher likelihood of
experiencing UTI during follow up (adjusted odds ratio [OR] = 1.54
[95% CI 1.47, 1.60]; p b 0.0001). Additionally, interactions between
T2DM and age (OR = 0.995 [0.992, 0.997]; p b 0.0001), as well asT2DM and gender (OR = 0.75 [0.68, 0.82]; p b 0.0001), were
statistically signiﬁcant when included in the regression model. This
indicates that signiﬁcant differences exist in the magnitude of the
effect of T2DM on UTI by age and gender. Thus, subgroup analyses by
gender and age groups were conducted. When stratiﬁed by gender,
the likelihoods were still signiﬁcantly higher for subjects with T2DM
compared to those without T2DM (women: OR = 1.43 [1.36, 1.50];
men: OR = 1.91 [1.76, 2.07]; p b 0.0001 for both). After stratifying by
age groups, the likelihood of experiencing UTI for those with T2DM
compared to those without T2DM was shown to decrease from
younger to older age groups. When stratiﬁed by age and gender
combined, the effect of T2DM on UTI was shown to diminish similarly
in men and women as they age (Table 3).4. Discussion
In the present study, the prevalence, incidence, and risk of UTIs in
patients with and without T2DM were evaluated using a large, US-
based commercial database. Our study showed a 54% increased risk of
UTI among subjects with newly diagnosed T2DM compared to those
Table 2
UTI prevalence and incidence of UTI during the 1-year follow-up period.
Prevalence cohorta Incidence cohortb
T2DM
n = 89,790
Without T2DM
n = 89,790
p Value T2DM
n = 82,239
Without T2DM
n = 84,941
p Value
n % n % n % n %
Total 8,456 9.42% 5,125 5.71% b0.0001 5,896 7.17% 3,738 4.40% b0.0001
By UTI components
UTI (599.0) 7,725 8.60% 4,591 5.11% b0.0001 5,372 6.53% 3,364 3.96% b0.0001
Cystitis (595) 1,249 1.39% 827 0.92% b0.0001 766 0.93% 524 0.62% b0.0001
Pyelonephritis (590.0, 590.1) 122 0.14% 65 0.07% b0.0001 79 0.10% 46 0.05% 0.002
By age groups (years)
18–24 128 10.89% 53 4.51% b0.0001 91 8.54% 42 3.80% b0.0001
25–34 331 9.93% 174 5.21% b0.0001 232 7.62% 134 4.22% b0.0001
35–44 1,075 9.30% 572 4.95% b0.0001 790 7.42% 436 3.97% b0.0001
45–54 2,078 8.35% 1,249 5.02% b0.0001 1,506 6.54% 925 3.90% b0.0001
55–64 2,702 8.80% 1,696 5.52% b0.0001 1,902 6.75% 1,257 4.31% b0.0001
65–74 786 9.14% 495 5.76% b0.0001 522 6.59% 344 4.24% b0.0001
75 and above 1,356 14.25% 886 9.32% b0.0001 853 10.23% 600 6.88% b0.0001
By sex
Male 2,284 5.01% 1,099 2.41% b0.0001 1,772 4.06% 891 2.00% b0.0001
Female 6,172 13.96% 4,026 9.10% b0.0001 4,124 10.69% 2,847 7.05% b0.0001
Baseline UTI
No 5,896 7.17% 3,738 4.40% b0.0001 NA NA NA NA NA
Yes 2,560 33.90% 1,387 28.60% b0.0001 NA NA NA NA NA
a All subjects regardless of UTI history.
b Subjects with no history of UTI during the baseline period.
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increased risk of 46% for newly diagnosed patients (Hirji et al., 2012).
Our study also examined the three individual components of our
composite UTI deﬁnition: UTI, cystitis, and pyelonephritis. UTIs were
the most commonly encountered infection among those with and
without T2DM, followed by cystitis and pyelonephritis. Although rates
of each type of infection were signiﬁcantly higher in subjects with
T2DM than in those without T2DM, it is interesting to note that the
relative proportion of all infections that were serious in nature
(i.e., pyelonephritis) was similar in those with and without T2DM.
Consistent with published literature, our results show that women
experience UTIs more frequently than men as an absolute risk,
regardless of T2DM diagnosis (Boyko et al., 2002, 2005; Hirji et al.,
2012; Jackson et al., 2004). However, interestingly, after adjusting for
potential confounders, T2DM diagnosis conferred a greater risk of UTI*P=0.0002, †P=0.0004, ‡P<0.0001; P=0.0003
Pe
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Men
Age Group
7518-24 25-34 35-44 45-54 55-64 65-74
*
†
‡ ‡
‡ ‡
‡
Fig. 2. Prevalence of UTI for menin the subgroup of men (OR = 1.91) than in the subgroup of women
(OR = 1.43). Considering that many other factors besides T2DM are
known to contribute to UTIs in women, it is conceivable that all other
factors being equal, T2DM could play a larger role in the UTI risk for
men. Although research regarding UTIs in male patients with T2DM is
lacking, a recent study by Drekonja, Rector, Cutting, & Johnson (2013)
reported that among male veterans the most common UTI-
predisposing condition was diabetes. Nonetheless, a study by Hirji
et al. (2012) found that overall there was no true difference between
men and women with T2DM in terms of the magnitude of UTI risk in
their study (adjusted RR among females was 1.53 [95% CI 1.45–1.60]
and among males was 1.49 [95% CI 1.38–1.60]). However, when men
and women were stratiﬁed into age groups, they found that among
women 18–39 years old, those with T2DM had 2.06 times the risk of
UTI versus those without T2DM. This is much lower than the risk forPe
rc
en
t
Women
Age Group
18-24 25-34 35-44 45-54 55-64 65-74 75
‡
‡
‡ ‡ ‡
‡
and women by age group.
Table 3
Conditional logistic regressions for UTI: overall and stratiﬁed by age, gender, and
history of UTI.
n Odds
ratio
95% CI p Value
Overall analysisa
T2DM vs. no T2DM 179,580 1.54 1.47, 1.60 b0.0001
Subgroup analyses: T2DM
vs. no T2DMb
By age groups (years)c
18–24 2,349 2.10 1.40, 3.18 0.0004
25–34 6,673 1.85 1.48, 2.31 b0.0001
35–44 23,111 1.83 1.63, 2.06 b0.0001
45–54 49,784 1.53 1.41, 1.66 b0.0001
55–64 61,447 1.49 1.38, 1.60 b0.0001
65–74 17,193 1.48 1.29, 1.71 b0.0001
75 and above 19,023 1.38 1.24, 1.53 b0.0001
By gendera
Male 91,136 1.91 1.76, 2.07 b0.0001
Female 88,444 1.43 1.36, 1.50 b0.0001
By history of UTId
No 167,180 1.57 1.49, 1.64 b0.0001
Yes 12,400 1.29 0.98, 1.71 0.072
By age groups (years) among femalec
18–24 1,262 1.85 1.17, 2.92 0.009
25–34 3,277 1.77 1.39, 2.27 b0.0001
35–44 11,106 1.71 1.49, 1.95 b0.0001
45–54 24,563 1.38 1.26, 1.51 b0.0001
55–64 30,173 1.38 1.26, 1.50 b0.0001
65–74 8,164 1.43 1.21, 1.70 b0.0001
75 and above 9,899 1.32 1.16, 1.50 b0.0001
By age groups (years) among malec
18–24 1,087 4.15 1.19, 14.45 0.025
25–34 3,396 2.26 1.30, 3.94 0.004
35–44 12,005 2.41 1.85, 3.13 b0.0001
45–54 25,221 2.28 1.89, 2.77 b0.0001
55–64 31,274 1.81 1.58, 2.08 b0.0001
65–74 9,029 1.54 1.18, 2.01 0.001
75 and above 9,124 1.54 1.26, 1.88 b0.0001
a Adjusted for age (year), health plan, baseline comorbidities, baseline UTI, and
number of physician visits in the pre-index year.
b Each row represents results from an individual regression.
c Adjusted for health plan, baseline comorbidities, baseline UTI, and number of
physician visits in the pre-index year.
d Adjusted for age (year), health plan, baseline comorbidities, and number of
physician visits in the pre-index year.
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UTI compared to their non-diabetic counterparts. Our additional
subgroup analyses by age groups among gender groups showed
similarmagnitude of differences betweenmen andwomen, though all
odds ratios indicated that the effect of T2DM on UTI for males is
numerically larger than their female counterparts.
In our study, a higher proportion of subjects with newly diagnosed
T2DM experienced UTIs at all age groups in both men and women
compared to those without T2DM. Similar to what was reported by
Hirji et al. (2012), the risk of UTI in those with T2DM compared to
those without T2DM tends to increase with decreasing age, despite
their gender. Again, this might suggest that as a person ages, T2DM
continues to contribute to UTI risk, albeit on a smaller relative scale
since many other competing risk factors begin to emerge.
Recurrence of UTI was demonstrated to be higher in subjects with
newly diagnosed T2DM than in those without T2DM during one year
of follow up, which corroborates previously published ﬁndings.
Schneeberger et al. (2008) reported a 16.1% recurrence rate in
women with diabetes compared to 12.2% in those without diabetes
(p = 0.003). Gorter, Hak, Zuithoff, Hoepelman, & Rutten (2010)
showed that 7.1% and 15.9% of women with diabetes versus 2.0% and
4.1% of women without diabetes experienced relapses and reinfec-
tions, respectively. We recognize that these values are higher than
what was found in our study (T2DM vs. without T2DM: 1.6% vs. 0.6%;
p b 0.0001). The observed differences could be attributed to varyingstudy designs, different deﬁnitions of recurrence, and our use of an
administrative claims database. We performed a sensitivity analysis
redeﬁning separate UTI events as those 1 month apart instead of
3 months apart and found a higher recurrence rate in both groups
(T2DM vs. without T2DM: 2.39% vs. 1.05%, p b 0.0001), with the
results following the same trend as our original results. In contrast,
Drekonja et al. (2013) did not ﬁnd that diabetes was associated with
early recurrence in their cohort of male veterans.
Our study also found that subjects with T2DM had a higher rate of
baseline UTI than those without T2DM (8.4% vs. 5.4%, p b 0.0001).
Although this could be the result of previously undiagnosed T2DM, it is
also possible that another predisposing factor is present. For example,
there is some evidence that obese subjects have an increased risk of
UTI (Saliba, Barnett-Griness, & Rennert, 2013; Semins, Shore, Makary,
Weiner, & Matlaga, 2012). Because obesity is also a risk factor for
T2DM, this could contribute to the between-group differences seen.
Unfortunately, information on weight was not available in the
database, so this relationship could not be assessed.
Certain limitations are present in this study. First, measurements
of glycemic control were not available due to lack of laboratory values
within claims data, and therefore, their potential inﬂuence on the risk
of UTI could not be assessed. Second, subjects with T2DM might visit
their physicians more frequently than the general population without
T2DM, and as a result might bemore likely to have their UTIs detected.
In order to account for this, our study controlled for baseline physician
visits in the conditional logistic regression models, and baseline
physician visits were highly correlated with post-index physician
visits (Pearson's r = 0.65, p b 0.0001). Third, as is the case with any
observational database study, unobserved confounders that were not
available in the data could have affected the study results, such as
body weight. Fourth, because this study utilized a claims database,
diagnosis of T2DM and all reports of UTI were based on ICD-9-CM
codes. Multiple studies have been conducted to validate the use of
diagnostic codes for diabetes and UTIs in administrative claims data
(Chen, Khan, Walker, & Quan, 2010; Linder, Bates, Williams, Connolly,
& Middleton, 2006). Speciﬁcally, UTI diagnoses from claims have
demonstrated a sensitivity, speciﬁcity, and positive predictive value of
100%, 87%, and 85%, respectively (Linder et al., 2006). The sensitivity
of diabetes diagnostic codes ranges from 59% to 86%, while speciﬁcity
and positive predictive values range from 85% to 100% and 63% to 99%,
respectively (Chen et al., 2010). Patients with undiagnosed or
unrecorded T2DM may be misclassiﬁed as patients without T2DM,
resulting in an underestimate of the differences between patients
with and without T2DM. Use of ICD-9-CM codes might also result in
underreporting of UTI. Further, without conﬁrmation by laboratory
testing, the potential exists to have both false positives (subjects who
had a UTI diagnosis code recorded by their physician, but a
subsequent urine culture was negative) and false negatives (subjects
who did not have a UTI diagnosis code recorded by their physician, but
a subsequent urine culture was positive). Fifth, for the recurrence
analysis, we utilized 3 months as the cut off for determining separate
UTI events; however, without a documented negative urine culture,
we cannot say with certainty that these are separate UTI events. Sixth,
the MarketScan databases are representative of the commercially
insured US population and those who have both Medicare and
supplemental coverage. Therefore, these results might not be
generalizable to other populations. Lastly, T2DM treatment, pregnan-
cy, history of urinary tract abnormalities, certain lifestyle factors (such
as sexual activity), and other comorbid conditions might potentially
affect the development of UTI and the study results. Despite these
limitations, to our knowledge, no studies have examined the
relationship between UTI and T2DM in a broad US-based cohort
that includes both men and women, and utilizes a well-matched
general population as a comparison group. Further strengths of our
study include the large sample size, one year of complete follow-up
for all subjects, and examination of UTI recurrence.
810 A.Z. Fu et al. / Journal of Diabetes and Its Complications 28 (2014) 805–810In summary, the presentﬁndings indicate that in this large US-based
commercially insured population, subjectswith newly diagnosed T2DM
were more likely to experience a UTI and recurrent UTIs compared to
subjects without T2DM. This relationship remained across all age and
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